Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer.


Journal

The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646

Informations de publication

Date de publication:
08 2019
Historique:
received: 07 12 2018
revised: 14 01 2019
accepted: 04 02 2019
pubmed: 7 2 2019
medline: 20 5 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

Hyaluronan (HA) is a linear nonsulfated glycosaminoglycan of the extracellular matrix that plays a pivotal role in a variety of biological processes. High-molecular weight HA exhibits different biological properties than oligomers and low-molecular weight HA. Depending on their molecular size, HA fragments can influence cellular behavior in a different mode of action. This phenomenon is attributed to the different manner of interaction with the HA receptors, especially CD44 and RHAMM. Both receptors can trigger signaling cascades that regulate cell functional properties, such as proliferation migration, angiogenesis, and wound healing. HA fragments are able to enhance or attenuate the HA receptor-mediated signaling pathways, as they compete with the endogenous HA for binding to the receptors. The modulation of these pathways could be crucial for the development of pathological conditions, such as inflammation and cancer. The primary goal of this review is to critically present the importance of HA molecular size on cellular signaling, functional cell properties, and morphology in normal and pathological conditions, including inflammation and cancer. A deeper understanding of these mechanisms could contribute to the development of novel therapeutic strategies.

Identifiants

pubmed: 30724463
doi: 10.1111/febs.14777
doi:

Substances chimiques

Extracellular Matrix Proteins 0
Hyaluronan Receptors 0
hyaluronan-mediated motility receptor 0
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2883-2908

Subventions

Organisme : General Secretariat for Research and Technology (GSRT)
Pays : International
Organisme : Hellenic Foundation of Research & Innovation (H.F.R.I)
Pays : International
Organisme : Advanced Research Activities in Biomedical and Agro alimentary Technologies
ID : MIS 5002469
Pays : International

Informations de copyright

© 2019 Federation of European Biochemical Societies.

Auteurs

Anastasia G Tavianatou (AG)

Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Greece.

Ilaria Caon (I)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Marco Franchi (M)

Department for Life Quality Studies, University of Bologna, Italy.

Zoi Piperigkou (Z)

Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Greece.
Foundation for Research and Technology-Hellas (FORTH) /Institute of Chemical Engineering Sciences (ICE-HT), Patras, Greece.

Devis Galesso (D)

Fidia Farmaceutici S.p.A., Abano Terme, Italy.

Nikos K Karamanos (NK)

Biochemistry, Biochemical Analysis & Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Greece.
Foundation for Research and Technology-Hellas (FORTH) /Institute of Chemical Engineering Sciences (ICE-HT), Patras, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH